Qiagen (NYSE:QGEN) Shares Purchased by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC grew its position in shares of Qiagen (NYSE:QGEN) by 24.1% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,751 shares of the company’s stock after purchasing an additional 4,608 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Qiagen were worth $958,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. CWM LLC raised its holdings in shares of Qiagen by 12.0% in the 2nd quarter. CWM LLC now owns 2,505 shares of the company’s stock valued at $103,000 after buying an additional 269 shares during the period. Eagle Asset Management Inc. lifted its position in shares of Qiagen by 2.2% during the fourth quarter. Eagle Asset Management Inc. now owns 20,338 shares of the company’s stock worth $883,000 after purchasing an additional 430 shares in the last quarter. TD Asset Management Inc lifted its position in shares of Qiagen by 1.0% during the fourth quarter. TD Asset Management Inc now owns 53,531 shares of the company’s stock worth $2,330,000 after purchasing an additional 554 shares in the last quarter. Riverview Trust Co purchased a new position in shares of Qiagen in the first quarter valued at approximately $28,000. Finally, Park Place Capital Corp acquired a new position in shares of Qiagen in the first quarter valued at approximately $36,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

QGEN has been the subject of several research reports. Robert W. Baird boosted their price target on shares of Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. boosted their price target on shares of Qiagen from $52.00 to $54.00 and gave the stock an “overweight” rating in a report on Tuesday, June 18th. Finally, Wolfe Research upgraded shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price objective on the stock in a report on Thursday, June 27th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $51.10.

Qiagen Price Performance

Shares of NYSE QGEN opened at $44.46 on Tuesday. The stock has a market cap of $10.15 billion, a P/E ratio of 29.84, a P/E/G ratio of 3.32 and a beta of 0.39. Qiagen has a twelve month low of $34.74 and a twelve month high of $47.44. The stock has a 50 day moving average of $44.98 and a two-hundred day moving average of $43.47. The company has a current ratio of 1.77, a quick ratio of 1.46 and a debt-to-equity ratio of 0.27.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, July 31st. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.52 by $0.03. Qiagen had a return on equity of 12.92% and a net margin of 3.75%. The business had revenue of $496.00 million for the quarter, compared to analyst estimates of $495.45 million. During the same quarter in the previous year, the company posted $0.53 earnings per share. The company’s revenue for the quarter was down .2% compared to the same quarter last year. On average, research analysts forecast that Qiagen will post 2.15 earnings per share for the current year.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.